Company Profile
Aridis Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- ARDS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.00 USD (0.00%)
Close
Last updated: August 3, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for ARDS.
Company overview
Business overview
Aridis Pharmaceuticals is a biotechnology company focused on antibody-based therapies for infectious disease and respiratory infections. Its story is centered on using targeted biologics to tackle stubborn pathogens.
Geographic Base and Sector Classification
Aridis is headquartered in the United States and listed on NASDAQ. It sits in small-cap anti-infective biotechnology.
Business Model Characteristics
The company depends on clinical validation, regulatory strategy, and the ability to keep a narrow pipeline funded. Investors usually watch proof-of-concept data and partnership interest.
Position Within the Biotechnology Landscape
Aridis occupies a niche anti-infective position within biotech. The stock is driven by whether its biologic approach can matter in difficult infection settings.
Future catalysts
Aridis is largely a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update. The market no longer treats it as a live development name.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aridis Pharmaceuticals (ARDS)?
Aridis Pharmaceuticals (ARDS) most recently closed at 0.00 USD, a 0.00% move versus the previous session.
What does Aridis Pharmaceuticals do?
Aridis Pharmaceuticals is a biotechnology company focused on antibody-based therapies for infectious disease and respiratory infections. Its story is centered on using targeted biologics to tackle stubborn pathogens.
On which exchange is ARDS stock listed?
Aridis Pharmaceuticals (ARDS) is associated with NASDAQ, United States, Biopharma.
What is Aridis?
Aridis is largely a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update.
Which conditions is Aridis Pharmaceuticals targeting with Aridis?
Aridis Pharmaceuticals is associated with respiratory disease based on its company overview and current catalyst commentary.
How does Aridis Pharmaceuticals describe recent progress with Aridis?
Aridis is largely a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update.
What is Pharmaceuticals?
Aridis Pharmaceuticals is a biotechnology company focused on antibody-based therapies for infectious disease and respiratory infections.
What should investors watch for with Pharmaceuticals?
Aridis is largely a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update. The market no longer treats it as a live development name.